PE20001396A1 - Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista - Google Patents

Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista

Info

Publication number
PE20001396A1
PE20001396A1 PE2000000011A PE0000112000A PE20001396A1 PE 20001396 A1 PE20001396 A1 PE 20001396A1 PE 2000000011 A PE2000000011 A PE 2000000011A PE 0000112000 A PE0000112000 A PE 0000112000A PE 20001396 A1 PE20001396 A1 PE 20001396A1
Authority
PE
Peru
Prior art keywords
opioid
agonist
delayed
combination
same
Prior art date
Application number
PE2000000011A
Other languages
English (en)
Inventor
Jurgen Betzing
Johannes Bartholomaus
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20001396A1 publication Critical patent/PE20001396A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A FORMULACIONES MEDICAMENTOSAS RETARDADAS QUE COMPRENDE a)UN OPIOIDE TAL COMO MORFINA, HIDROMORFONA, CODEINA, OXICODONA, DIHIDROCODEINA, DEXTROPROPOXIFEN, BUPRENORFINA, LEVOMETADONA, FENTANIL, SUFENTANIL, DE PREFERENCIA MORFINA TRAMADOL, ENTRE OTROS; O UNA SAL FISIOLOGICAMENTE ACEPTABLE ; b)UN O-AGONISTA TAL COMO CLONIDINA, GUANFACINA, GUANABENZ, LOFEXIDINA, ADRENALINA, METILDOPA, NORADRENALINA, METOXAMINA, OXIMETAZOLINA, XILOMETAZOLINA, TERIZOLINA, ENTRE OTROS; c)MONOACIDO FOSFATO CALCICO; d)EXCIPIENTES TAL COMO AGLUTINANTES, DISGREGANTES, DILUYENTES COLORANTES ENTRE OTROS. LA FORMULACION MEDICAMENTOSA ES ADMINISTRADA EN FORMA ORAL, PARENTERAL, TRANSDERMICA Y UNA O AMBAS SUSTANCIAS ACTIVAS SE ENCUENTRA EN FORMA RETARDADA. LA RELACION PONDERAL DEL OPIOIDE CON RESPECTO AL O-AGONISTA ES DE 20 A 1 HASTA 10 A 1. LA FORMULACION ES UTILIZADO EN ESTADOS DE DOLOR AGUDOS O CRONICOS
PE2000000011A 1999-01-18 2000-01-06 Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista PE20001396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901684 1999-01-18

Publications (1)

Publication Number Publication Date
PE20001396A1 true PE20001396A1 (es) 2000-12-23

Family

ID=7894563

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000011A PE20001396A1 (es) 1999-01-18 2000-01-06 Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista

Country Status (15)

Country Link
US (1) US20020044966A1 (es)
EP (1) EP1143936A2 (es)
JP (1) JP2002534458A (es)
AR (1) AR022252A1 (es)
AU (1) AU772886B2 (es)
BR (1) BR0000578A (es)
CA (1) CA2359273A1 (es)
CO (1) CO5160243A1 (es)
HU (2) HUP0105043A3 (es)
NO (2) NO20000225D0 (es)
NZ (1) NZ513501A (es)
PE (1) PE20001396A1 (es)
SK (1) SK10012001A3 (es)
UY (1) UY25936A1 (es)
WO (1) WO2000041681A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107213128A (zh) 1999-10-29 2017-09-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CA2424021A1 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
KR100968128B1 (ko) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
EP1395243A2 (en) * 2001-05-31 2004-03-10 SkyePharma Inc. Encapsulation of nanosuspensions in liposomes and microspheres
EP1414458B1 (en) * 2001-07-06 2007-04-11 Endo Pharmaceuticals Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US7854230B2 (en) * 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
US7485323B2 (en) * 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
NZ565649A (en) * 2005-07-28 2011-03-31 Shire Llc Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
EP1931346B1 (en) * 2005-09-09 2012-07-18 Angelini Labopharm, LLC Trazodone composition for once a day administration
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
MX2009013384A (es) 2007-06-08 2010-01-25 Addrenex Pharmaceuticals Inc Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica.
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
WO2009130715A1 (en) * 2008-04-25 2009-10-29 Cadila Healtcare Limited Rapidly disintegrating oral compositions of tramadol
WO2009158477A1 (en) * 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
CN102196819B (zh) * 2008-10-30 2013-01-30 国立大学法人冈山大学 局部麻醉用组合物
MX348361B (es) * 2009-12-17 2017-06-07 Cima Labs Inc Formulaciones resistentes al abuso.
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
CA2991217C (en) 2010-12-22 2020-06-09 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
WO2013052770A1 (en) 2011-10-05 2013-04-11 Sanders Jennifer L Methods and compositions for treating foot or hand pain
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
TWI629066B (zh) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
EP3054932B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
CN105764496B (zh) 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN112494486B (zh) * 2020-12-07 2022-01-21 深圳善康医疗健康产业有限公司 一种用于减轻或消除阿片戒断综合症的药物组合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946848A (en) * 1985-10-29 1990-08-07 Baker Cumins Dermatologicals, Inc. Method of treating pruritus with nalmefene and clonidine
PT99629A (pt) * 1991-11-28 1993-05-31 Antonio Feria Reis Valle Metodo de desintoxicacao de opiaceos
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
DE19758564A1 (de) * 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung

Also Published As

Publication number Publication date
AR022252A1 (es) 2002-09-04
US20020044966A1 (en) 2002-04-18
JP2002534458A (ja) 2002-10-15
AU2109000A (en) 2000-08-01
NO20013302L (no) 2001-07-03
WO2000041681A3 (de) 2000-12-07
CO5160243A1 (es) 2002-05-30
CA2359273A1 (en) 2000-07-20
SK10012001A3 (sk) 2002-01-07
HUP0105043A3 (en) 2005-06-28
EP1143936A2 (de) 2001-10-17
NO20000225D0 (no) 2000-01-17
NZ513501A (en) 2003-11-28
BR0000578A (pt) 2001-08-14
NO20013302D0 (no) 2001-07-03
HU0000139D0 (en) 2000-03-28
HUP0105043A2 (en) 2002-06-29
UY25936A1 (es) 2001-07-31
AU772886B2 (en) 2004-05-13
WO2000041681A2 (de) 2000-07-20

Similar Documents

Publication Publication Date Title
PE20001396A1 (es) Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
ES2091441T3 (es) Composicion farmaceutica.
CO5261517A1 (es) Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis
HUP0203733A2 (en) Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
BRPI0418228A (pt) forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
RS51764B (en) TRANSDERMAL PHARMACEUTICAL COMPOSITION
BRPI0309544B8 (pt) preparação farmacêutica oral estável ao armazenamento compreendendo oxicodona e naloxona
NZ503233A (en) Synergistic analgesic combination of opioid analgesic and COX-2 inhibitor
CN1267215A (zh) 含有泡腾酸碱对的药物组合物
ID27503A (id) Tts yang mengandung antioksidan
HUP0401174A3 (en) Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compounds
ES2963078T3 (es) Formulaciones de liberación inmediata disuasorias del abuso que comprenden polisacáridos no celulósicos
DE60024491D1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
RU2000126790A (ru) Композиция, предназначенная для лечения алкогольной и лекарственной зависимости, содержащая опиоидный антагонист и модулятор nmda рецепторного комплекса
ATE243504T1 (de) Cefadroxilmonohydrat tablettenformulierung
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
IL150528A0 (en) Ibuprofen containing active agent preparation
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed